Chemotherapy with pegylated liposomal doxorubicin and cisplatin in recurrent platinum-sensitive epithelial ovarian cancer
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, cilt.13, sa.4, ss.330-334, 2008 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 13 Sayı: 4
- Basım Tarihi: 2008
- Doi Numarası: 10.1007/s10147-007-0757-8
- Dergi Adı: INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.330-334
- İstanbul Üniversitesi Adresli: Evet
Özet
Background. Pegylated liposomal doxorubicin (PLD) is the only nonplatinum agent to significantly improve survival in patients with platinum-sensitive recurrent ovarian cancer. The present study was designed to assess the efficacy and safety of PLD plus cisplatin combination therapy in these patients.